DelveInsight’s, “Atrial Fibrillation Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the Atrial Fibrillation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atrial Fibrillation pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Atrial Fibrillation Treatment Landscape. Click here to read more @ https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight
Key Takeaways from the Atrial Fibrillation Pipeline Report
- In January 2026, Janssen Research & Development LLC announced a phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation.
- In January 2026, Novartis Pharmaceuticals conducted a study to evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN605 in Participants With Atrial Fibrillation.
- DelveInsight’s Atrial Fibrillation pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Atrial Fibrillation treatment.
- The leading Atrial Fibrillation Companies such as HUYA Bioscience, InCarda Therapeutics Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
- Promising Atrial Fibrillation Pipeline Therapies such as Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
Stay informed about the cutting-edge advancements in Atrial Fibrillation Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Atrial Fibrillation Clinical Trials Assessment
Atrial Fibrillation Overview
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, characterized by an irregular and often rapid heartbeat caused by disorganized electrical signals in the atria. This abnormal rhythm leads to ineffective atrial contraction and impaired blood flow to the ventricles, increasing the risk of serious cardiovascular complications. AF can be classified into paroxysmal, persistent, long-standing persistent, and permanent forms, based on the duration and pattern of the arrhythmia. The condition may be asymptomatic in some individuals, while others experience symptoms such as palpitations, fatigue, shortness of breath, dizziness, chest discomfort, and reduced exercise tolerance.
Atrial Fibrillation Emerging Drugs Profile
- Etripamil: Milestone Pharmaceuticals Inc.
Etripamil is an investigational, fast-acting L-type calcium channel blocker delivered as a nasal spray, developed for on-demand, self-administered treatment of paroxysmal supraventricular tachycardia (PSVT). As Milestone’s lead candidate, Etripamil is designed to offer rapid symptom relief outside of a clinical setting, potentially transforming the management of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR). It is currently in Phase III development for AFib-RVR.
- HBI-3000: HUYA Bioscience
HBI-3000 is a multi-ion channel blocker with in vitro inhibitory effects on INa-Peak, INa-Late, ICa, L and IKr being developed by HUYABIO International for the conversion of recent onset atrial fibrillation. The drug’s preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing. Data from the first in human Phase I trial of the IV formulation were presented during a poster session at the American Heart Association 2019 annual meeting. Currently, the drug is in the Phase II stage of its development for the treatment of Atrial Fibrillation.
Atrial Fibrillation Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
- Atrial Fibrillation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.
Get a detailed analysis of the latest innovations in the Atrial Fibrillation pipeline. Explore DelveInsight’s expert-driven report today! @ Atrial Fibrillation Unmet Needs
Atrial Fibrillation Companies
HUYA Bioscience, InCarda Therapeutics Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Atrial Fibrillation Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in Atrial Fibrillation Treatment by visiting our website. Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspectives
Scope of the Atrial Fibrillation Pipeline Report
- Coverage- Global
- Atrial Fibrillation Companies- HUYA Bioscience, InCarda Therapeutics Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
- Atrial Fibrillation Pipeline Therapies- Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
- Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Atrial Fibrillation Pipeline on our website @ Atrial Fibrillation Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Atrial Fibrillation: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Atrial Fibrillation– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Etripamil: Milestone Pharmaceuticals Inc.
- Mid Stage Products (Phase II)
- Etripamil: Milestone Pharmaceuticals Inc
- Early Stage Products (Phase I)
- HBI-3000: HUYA Bioscience
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Atrial Fibrillation Key Companies
- Atrial Fibrillation Key Products
- Atrial Fibrillation- Unmet Needs
- Atrial Fibrillation- Market Drivers and Barriers
- Atrial Fibrillation- Future Perspectives and Conclusion
- Atrial Fibrillation Analyst Views
- Atrial Fibrillation Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
